ETHZilla (ETHZ) Stock Price

ETHZilla Price

NASDAQ·CLOSED
4.48
​
Market closed

ETHZilla stock price

Access this data via the Eulerpool API

ETHZilla business model & stock analysis

180 Life Sciences Corp. develops pharmaceuticals for chronic pain and inflammatory diseases. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2017-06-27. IV., is a research and development company. The firm is focused on research into solving one of the diseases is inflammation. The firm consists of three programs developing drugs in separate areas of inflammation. The Company’s pipeline, including Fibrosis and Anti-TNF, SCAs and a7nAChR. The Fibrosis and Anti-TNF treats diseases like Dupuytren’s contracture, frozen shoulder, polycystic ovarian disease (POCD), nonalcoholic steatohepatitis (NASH). The SCAs includes chronic pain and early arthritis. The a7nAChR includes smoking cessation induced ulcerative colitis.

Frequently asked questions about ETHZilla

7 analysts currently rate the ETHZilla stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect ETHZilla to generate revenue of 17.96 M USD and earnings per share of -8.40 USD.

Converted at the current exchange rate, the ETHZilla share trades at 4.00 EUR (4.48 USD).

The ETHZilla share (ETHZ) is listed on 1 stock exchanges, including: NASDAQ (ATNF).

The expected revenue of ETHZilla is 17.96 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of ETHZilla is -104.27 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of ETHZilla is currently -0.53. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the ETHZilla stock.

The price-to-sales ratio (P/S) of ETHZilla is currently 3.10. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the ETHZilla stock.

The Eulerpool Quality Score for ETHZilla is 2/10.

The ISIN of ETHZilla is US68236V4014. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of ETHZilla is A2QJX5. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of ETHZilla is ETHZ. The ticker symbol is used to trade ETHZilla shares on the stock exchange.

Fair ValueTerminal
4.39 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
1.64 M USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jun 27, 2017
ISIN
US68236V4014
Cusip
68236V104
Sedol
BMB6BH4
Market capitalization
85.16 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-0.53
P/Ee 2027
-5.13
P/Ee 2028
5.40
P/Ee 2029
—
P/S
P/Se
3.10
EV/EBIT
32.91
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-187.98 %
Last updated Oct 10, 2026, 5:56 PM

ETHZilla Peer Group

ETHZilla Ticker

NASDAQ · ATNF

All fundamentals and in-depth analysis of ETHZilla

Our stock analysis for ETHZilla stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ETHZilla. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.